US0198181036 - Common Stock - After market: 3.76 0 (0%)
NASDAQ:ALVR (5/27/2022, 3:52:34 PM)+0.15 (+4.16%)
|GICS Sector||Health Care|
|Earnings (Last)||05-05 2022-05-05/bmo||Earnings (Next)||08-04 2022-08-04|
|Ins Owners||7.54%||Inst Owners||41.96%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The company is headquartered in Waltham, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2020-07-30. The firm is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). VST manufacturing platform enables the reproducible generation of single-virus and multi-virus specific cell therapeutic candidates.
1100 Winter Street
Waltham MASSACHUSETTS 02142
CEO: David Hallal
AlloVir (ALVR) stock is taking off on Wednesday following an update from the U.S. Food and Drug Administration (FDA) on posoleucel.
Here you can normally see the latest stock twits on ALVR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.